Učitavanje...

鉴定晚期肺腺癌EGFR-T790M耐药基因突变候选生物标志物

BACKGROUND AND OBJECTIVE: Osimertinib is approved by Food and Drug Administration for patients with advanced non-small cell lung cancer carrying EGFR-T790M mutations. Osimertinib therapy was missed in many patients who were unable to perform biopsy due to occult lesion progression or weak body. In t...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Zhongguo Fei Ai Za Zhi
Format: Artigo
Jezik:Inglês
Izdano: 中国肺癌杂志编辑部 2020
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7679218/
https://ncbi.nlm.nih.gov/pubmed/33203197
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2020.104.20
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!